Now Playing
Opinion|Videos|October 15, 2024
Colorectal Cancer: Rising Prevalence and the Promise of ctDNA
Panelists discuss how colorectal cancer rates are increasing, particularly among younger adults, while highlighting the potential of circulating tumor DNA (ctDNA) technology to improve early detection and treatment monitoring.
Advertisement
Episodes in this series
Advertisement
Related to this article
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
In a phase 3 trial, the Breast Cancer Locator was noninferior to wire localization and lowered positive margin rates in nonpalpable breast cancer.
ASCENT-03 subgroup data show sacituzumab govitecan improved PFS vs chemotherapy across subgroups in untreated metastatic TNBC.
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
Bispecific antibodies targeting PD-L1 showed activity across first-, second-, and later-line advanced neuroendocrine carcinoma in 3 trials presented at ESMO 2026.
Petosemtamab plus pembrolizumab cut the risk of death by 50% vs pembrolizumab alone in first-line recurrent or metastatic PD-L1–positive head and neck cancer.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
The phase 3 IMpactMF study will be discontinued after an independent committee determined it was unlikely to meet its primary end point of overall survival.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Pembrolizumab Plus Chemo Improves PFS in PD-L1+ HR+/HER2– Breast Cancer
4
CEA-High Expression Shows Early Promise as a Biomarker for BG-C477 in NSCLC
5